比生群用于非小细胞肺癌的II期试验。
Phase II trial of bisantrene in non-small cell lung cancer.
作者信息
Miller T P, Ahmann F R, Mackel C, Greenberg B R, Alberts D S
出版信息
Invest New Drugs. 1985;3(4):393-5. doi: 10.1007/BF00170764.
PMID:4086247
Abstract
Eighteen evaluable patients with non-small cell lung cancer (NSCLC) were treated with bisantrene at a dose of 200 mg/m2 once a week for 3 consecutive weeks. Courses of treatment were repeated every 4 weeks. This dose schedule caused leukopenia (less than 3,500 cells/microl) in all patients. There were no objective responses in 18 patients. Bisantrene in this myelosuppressive dose schedule did not have significant activity in patients with NSCLC.
摘要
18例可评估的非小细胞肺癌（NSCLC）患者接受了比生群治疗，剂量为200mg/m²，每周1次，连续3周。每4周重复治疗疗程。该剂量方案导致所有患者出现白细胞减少（低于3500个细胞/微升）。18例患者均未出现客观缓解。在这种骨髓抑制剂量方案下，比生群对NSCLC患者没有显著活性。
Zotero 插件